IL308071A - Process for preparing NLRP3 inhibitors - Google Patents
Process for preparing NLRP3 inhibitorsInfo
- Publication number
- IL308071A IL308071A IL308071A IL30807123A IL308071A IL 308071 A IL308071 A IL 308071A IL 308071 A IL308071 A IL 308071A IL 30807123 A IL30807123 A IL 30807123A IL 308071 A IL308071 A IL 308071A
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- nlrp3 inhibitors
- nlrp3
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 | ||
| PCT/EP2022/067126 WO2022268935A2 (en) | 2021-06-23 | 2022-06-23 | Novel process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308071A true IL308071A (en) | 2023-12-01 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308071A IL308071A (en) | 2021-06-23 | 2022-06-23 | Process for preparing NLRP3 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (zh) |
| EP (1) | EP4359385A2 (zh) |
| JP (1) | JP2024524215A (zh) |
| KR (1) | KR20240024842A (zh) |
| CN (1) | CN118019727A (zh) |
| AR (1) | AR126215A1 (zh) |
| AU (1) | AU2022300325A1 (zh) |
| CA (1) | CA3219597A1 (zh) |
| IL (1) | IL308071A (zh) |
| TW (1) | TW202317514A (zh) |
| WO (1) | WO2022268935A2 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024133610A1 (en) * | 2022-12-23 | 2024-06-27 | F. Hoffmann-La Roche Ag | Proccesses for the preparation of an nlrp3 inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997041119A1 (en) * | 1997-05-02 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| PT1340757E (pt) * | 2000-11-16 | 2006-12-29 | Sankyo Co | Derivados 1-metilcarbapenem |
| EP1403255A4 (en) * | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
| AU2003223631B2 (en) * | 2002-04-18 | 2006-07-20 | Schering Corporation | 1-(4-Piperidinyl) benzimidazolones as histamine H3 antagonists |
| WO2005035495A2 (en) * | 2003-10-08 | 2005-04-21 | Nicholas Piramal India Limited | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| KR20090110950A (ko) * | 2007-02-22 | 2009-10-23 | 메르크 세로노 에스. 에이. | (피라진 유도체) 퀴녹살린 화합물 및 이의 용도 |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| WO2017095758A1 (en) * | 2015-12-01 | 2017-06-08 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| PL3661925T3 (pl) * | 2017-07-07 | 2022-02-28 | Inflazome Limited | Nowe związki sulfonamidowo karboksyamidowe |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| JP2021519337A (ja) * | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN112533913A (zh) * | 2018-05-04 | 2021-03-19 | 英夫拉索姆有限公司 | 新颖化合物 |
| PE20211071A1 (es) * | 2018-09-21 | 2021-06-09 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
-
2022
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko unknown
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en active Application Filing
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022268935A2 (en) | 2022-12-29 |
| JP2024524215A (ja) | 2024-07-05 |
| US20240150291A1 (en) | 2024-05-09 |
| CN118019727A (zh) | 2024-05-10 |
| AU2022300325A8 (en) | 2023-11-16 |
| EP4359385A2 (en) | 2024-05-01 |
| WO2022268935A3 (en) | 2023-02-02 |
| KR20240024842A (ko) | 2024-02-26 |
| CA3219597A1 (en) | 2022-12-29 |
| AU2022300325A1 (en) | 2023-11-02 |
| AR126215A1 (es) | 2023-09-27 |
| TW202317514A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287042A (en) | Inflammatory inhibitors of nlrp3 | |
| IL280336A (en) | NLRP3 inflammasome inhibitors | |
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| IL287902A (en) | Methods of administering certain vmat2 inhibitors | |
| EP3982949A4 (en) | MRSA1 INHIBITORS | |
| IL307188A (en) | NLRP3 inhibitors | |
| EP3502105B8 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| ZA201803942B (en) | Novel processes for preparation of integrase inhibitor | |
| EP3980011A4 (en) | MRSA1 INHIBITORS | |
| IL306022A (en) | NLRP3 inflammasome inhibitors | |
| IL290185A (en) | Crystalline forms of risdiplam and their preparation process | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL308071A (en) | Process for preparing NLRP3 inhibitors | |
| IL290181A (en) | Process for the preparation of Fluensulfone | |
| IL289904A (en) | A process for preparing biphenylamines | |
| IL289453A (en) | A process for the preparation of ridinilazole and crystalline forms thereof | |
| IL289214A (en) | Crystalline forms of plasma kallikrein inhibitors | |
| EP3981768A4 (en) | POLYMORPH OF CDK9 INHIBITOR AND METHOD OF MANUFACTURE OF POLYMORPH AND USE THEREOF | |
| IL309680A (en) | NLRP3 inflammasome inhibitors | |
| IL280312A (en) | Process for preparing bromodomain inhibitors | |
| EP3989975A4 (en) | METHOD FOR PRODUCING ABROCITINIB | |
| EP4096662A4 (en) | PROCESS FOR PREPARING LASMIDITAN | |
| EP3993792A4 (en) | PROCESS FOR THE MANUFACTURE OF EDOXABAN | |
| IL311430A (en) | PROCESS FOR THE PREPARATION OF SAFINAMIDE |